Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors With High Proliferation or Low Proliferation With Metastatic Nodes. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

NCT02603679 is registered in ClinicalTrials.gov with Thomas Hatschek as lead sponsor.

NCT NCT02603679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02603679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors With High Proliferation or Low Proliferation With Metastatic Nodes. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Lead sponsor
Thomas Hatschek
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 28, 2015
Completion date
December 31, 2031
Enrollment
181 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage breast carcinoma, estrogen receptor positive tumor